Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903187 · ClinicalTrials.gov registry record · NA
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT01903187 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 4 participants.
The verdict
NCT01903187, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
Interventions
- PROCEDURE Sham
- DEVICE EnligHTN Renal Denervation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903187
The ClinicalTrials.gov registry entry for NCT01903187 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT01903187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903187 about?
NCT01903187 is a clinical study titled "EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension". The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
What is the current status of trial NCT01903187?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2013-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01903187?
The interventions under investigation include: Sham (PROCEDURE), EnligHTN Renal Denervation (DEVICE).
Who is sponsoring clinical trial NCT01903187?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.